Año 2017 / Volumen 109 / Número 8
Editorial
The complexity of evaluating and increasing adherence in inflammatory bowel disease

539-541

DOI: 10.17235/reed.2017.5143/2017

Petra Weimers, Johan Burisch, Pia Munkholm,

Resumen
Inflammatory bowel diseases (IBDs), due to their chronic and progressive nature, require lifelong treatment to relief and/or prevent inflammation and symptoms, obtaining mucosal healing at best. Therefore, adherence to treatment is an essential topic to address when treating patients with IBD. Nonetheless, adherence remains a common and complex issue in IBD care. Patient characteristics such as young age, male sex and employment has previously been verified as possible predictors of non-adherence. Additionally, evaluating adherence in itself is a challenge since both accurate and easy-to-use screening tools as well as golden standards are lacking.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114(1):39–43.
2. Severs M, Zuithoff PNPA, Mangen M-JJ, et al. Assessing Self-reported Medication Adherence in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Sep;22(9):2158–64.
3. Kane S V., Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001 Oct;96(10):2929–33.
4. De Castro M-L, Sanromán L, Martín A, et al. Assessing medication adherence in Inflammatory Bowel Diseases. A comparison between a self-administered scale and a pharmacy refill index. Spanish J Gastroenterol. 2017;In press.
5. Kane S, Becker B, Scott Harmsen W, et al. Use of a Screening Tool to Determine Nonadherent Behavior in Inflammatory Bowel Disease. Am J Gastroenterol. 2012;107(10).
6. Bermejo F, López-San Román A, Algaba A, et al. Factors that modify therapy adherence in patients with inflammatory bowel disease. J Crohn’s Colitis. 2010;4:422–6.
7. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Mar;23(5):577–85.
8. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther. 1984;6(5):592–9.
9. Algaba A, Guerra I, García García de Paredes A, et al. What is the real-life maintenance mesalazine dose in ulcerative colitis? Rev Española Enfermedades Dig. 2016 Feb;109(2):114–21.
10. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008 Feb 28;27:9–14.
11. Greenley RN, Kunz JH, Walter J, et al. Practical strategies for enhancing adherence to treatment regimen in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Jun;19(7):1534–45.
12. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided “Constant-care” approach. Gut. 2010 Dec;59(12):1652–61.
13. Cross RK, Cheevers N, Rustgi A, et al. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis (UC HAT). Inflamm Bowel Dis. 2012;18(6):1018.
14. Hommel KA, Hente E, Herzer M, et al. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol. 2013 Apr;25(4):469–73.
15. Carlsen K, Jakobsen C, Houen G, et al. Self-managed eHealth Disease Monitoring in Children and Adolescents with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Feb;1.
16. Pedersen N, Elkjaer M, Duricova D, et al. eHealth: individualisation of infliximab treatment and disease course via a self-managed web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012 Nov;36(9):840–9.
17. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014 Dec;20(12):2276–85.
18. Elkjaer M, Burisch J, Avnstrøm S, et al. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol. 2009 Jun;22(6):1.
19. de Jong M, van der Meulen-de Jong A, Romberg-Camps M, et al. Development and Feasibility Study of a Telemedicine Tool for All Patients with IBD. Inflamm Bowel Dis. 2017 Apr;23(4):485–93.
20. Bager P, Julsgaard M, Vestergaard T, et al. Scandinavian Journal of Gastroenterology Adherence and quality of care in IBD Adherence and quality of care in IBD. Scand J Gastroenterol. 2016;5111:1326–31.
Artículos relacionados

Carta

Linfoma T hepatoesplénico y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2023.9472/2023

Carta

Apoptotic colopathy as a manifestation of Good’s syndrome

DOI: 10.17235/reed.2021.8297/2021

Original

Radon exposure and inflammatory bowel disease in a radon prone area

DOI: 10.17235/reed.2021.8239/2021

Revisión

Enfermedad inflamatoria intestinal y trasplante de órganos sólido

DOI: 10.17235/reed.2020.7361/2020

Editorial

Diet in the etiology of inflammatory bowel disease

DOI: 10.17235/reed.2018.6119/2018

Caso Clínico

Lesiones serradas en pacientes con enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2019.5910/2018

Editorial

Redes sociales online y enfermedad inflamatoria intestinal

DOI: 10.17235/reed.2018.5496/2018

Carta al Editor

Hipertensión portal idiopática por tiopurinas

DOI: 10.17235/reed.2018.5256/2017

Instrucciones para citar
Weimers P, Burisch J, Munkholm P. The complexity of evaluating and increasing adherence in inflammatory bowel disease. 5143/2017


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 536 veces.
Este artículo ha sido descargado 154 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 27/06/2017

Aceptado: 06/07/2017

Prepublicado: 14/07/2017

Publicado: 31/07/2017

Tiempo de prepublicación: 17 días

Tiempo de edición del artículo: 34 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas